Diabetes, Vol 37, Issue 10 1340-1345, Copyright © 1988 by American Diabetes Association

ARTICLES

ATPase activity defects in alloxan-induced diabetic sciatic nerve recovered by ganglioside treatment

R Bianchi, P Marini, S Merlini, M Fabris, C Triban, E Mussini and MG Fiori
Mario Negri Institute for Pharmacological Research, Milan, Italy.

ATPase activities were measured in sciatic nerves from rats with alloxan-induced diabetes (ALX-D) of various duration (2 wk, 5 wk, 9 wk, and 6 mo). Our data confirm that sciatic nerve Na+-K+-ATPase abnormalities are present very early in ALX-D rats, similar to results previously described in streptozocin-induced diabetic rats, spontaneously diabetic BB Wistar rats, and ALX-D rabbits. Na+-K+-ATPase activity decreased by 26-47% in ALX-D rats compared with age-matched controls. Ganglioside treatment (10 mg/kg i.p. for 10 or 30 days starting 1 wk after ALX injection) completely impeded the enzyme reduction. The effect observed at the end of either 10 or 30 days of treatment lasted greater than or equal to 1 mo. Chronic diabetic groups treated for 30 days before killing also presented normal ATPase activity at the end of treatment. Therefore, gangliosides are effective on Na+-K+-ATPase even in animals with a longer duration of diabetes. The maintenance of fairly normal ATPase activity by ganglioside treatment could mirror a more general recovery from early metabolic dysfunction and/or late structural abnormalities in diabetic nerve fibers.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. Bianchi, B. Buyukakilli, M. Brines, C. Savino, G. Cavaletti, N. Oggioni, G. Lauria, M. Borgna, R. Lombardi, B. Cimen, et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy PNAS, January 20, 2004; 101(3): 823 - 828. [Abstract] [Full Text] [PDF]